# Research timeline and gaps: Diet–Heart (Saturated Fat) Hypothesis

Selected publication milestones through 9 October 2026. These dates identify source publication years, not priority claims or a comprehensive history.

**1979 — Finnish hospital dietary periods test cholesterol and coronary outcomes in a limited historical design.** [PMID 393644](https://pubmed.ncbi.nlm.nih.gov/393644/).

**1989 — Original Minnesota trial clinical report; one parent study with the later reanalysis.** [PMID 2643423](https://pubmed.ncbi.nlm.nih.gov/2643423/).

**2013 — Recovered Sydney trial data sharpen uncertainty about intervention composition and mortality.** [PMID 23386268](https://pubmed.ncbi.nlm.nih.gov/23386268/).

**2016 — Recovered Minnesota data distinguish lipid response from observed mortality.** [PMID 27071971](https://pubmed.ncbi.nlm.nih.gov/27071971/).

**2017 — FOURIER tests pharmacological LDL lowering with clinical event endpoints.** [PMID 28304224](https://pubmed.ncbi.nlm.nih.gov/28304224/).

**2020 — Multivariable genetics prioritizes apoB across correlated lipid measures.** [PMID 32203549](https://pubmed.ncbi.nlm.nih.gov/32203549/).

**2024 — RISSCI-1 documents heterogeneous responses in a sequential design.** [PMID 39111551](https://pubmed.ncbi.nlm.nih.gov/39111551/).

**2026 — Response-selected RISSCI-2 examines a proposed absorption explanation.** [PMID 42664559](https://pubmed.ncbi.nlm.nih.gov/42664559/).

## Research gaps

Selective diet-specific clinical mediation remains weaker than particle causality.

Cis-MUFA and cis-PUFA, individual SFA species and food matrices need separate effect estimates.

Historical trans-fat exposure and incomplete data recovery remain unresolved; contamination must not be asserted as an established explanation of nulls.

Mean response and responder-defined follow-up are distinct populations.

More diverse clinical populations and complete correction/supplement checks are needed.

## Study that would resolve the boundary

Independently run, preregistered long-term isoenergetic replacement trial with fixed SFA species, cis-PUFA/cis-MUFA comparators, matched food matrices, trans-fat measurement, sustained apoB separation and blinded adjudicated ASCVD outcomes; prospectively test mediation and competing metabolic pathways.